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Abstract: Diabetic neuropathic foot ulcers represent a serious health care burden to patients and 
to society. While the management of chronic diabetic foot ulcers has improved in recent years, 
it remains a frustrating problem for a variety of clinicians. This review examines the scientiﬁ  c 
underpinnings supporting the use of becaplermin (Regranex®; Ortho-McNeil Pharmaceutical, 
Raritan, NJ), or recombinant human platelet-derived growth factor (rhPDGF-BB), in diabetic 
forefoot wounds. An emphasis is placed upon proper medical and surgical care of diabetic 
foot wounds, as multiple studies have demonstrated that the success of this growth factor 
in accelerating healing is ultimately dependent on proper ulcer care. A focus on the cost-
effectiveness of this form of therapy in the treatment of diabetic foot ulcers is also outlined.
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Introduction
Diabetes mellitus leads to a host of serious complications in multiple organ systems. 
Lower extremity ulcers represent a serious health care burden in terms of harm to a 
patient’s health and cost to society. This burden is expanding tremendously, as the inci-
dence of diabetes in industrialized as well as developing countries is growing in epidemic 
proportions. The annual incidence of foot ulcers in diabetic patients in the United States 
is estimated to be 2% of the greater than 20 million people affected by this disease, 
and this number rises to 5  7.5% among those with peripheral neuropathy. Eventually, 
15%–25% of all people with diabetes will develop a foot ulcer at some point in their 
lifetime. The management of foot ulcers and their associated morbidities is a leading 
cause of hospitalizations, and the occurrence of a foot ulcer signiﬁ  cantly increases the 
risk of an amputation in diabetic patients. In fact, approximately 85% of all amputations 
for diabetic limbs were preceded by ulcers, culminating in 60,000–80,000 amputations 
performed yearly secondary to the failure of such wounds to heal. Indeed, most lower 
extremity amputations are performed in diabetic patients. The risk of death for a diabetic 
person who ends up with a below-knee amputation is 50% over 5 years. Much of this 
increased risk is attributable to the increased work of ambulating with a prosthetic limb 
and the resulting myocardial strain in these patients, most of whom have cardiovascular 
disease (Centers for Disease Control and Prevention 2005; Cowie et al 2006).
It is sobering to think that most of these problems are avoidable. Most ulcers can 
be prevented with intense patient education, proper orthotic use, and vigilant foot care. 
Once diagnosed, most forefoot ulcers are curable without major surgical intervention. 
The onset of a mal perforant ulcer should mobilize a set of resources consisting of 
adherence to good wound care, ofﬂ  oading, and dedicated monitoring. These resources 
may include growth factor therapy in select circumstances. However, the proper use 
of biologics is only undertaken by understanding the principles of diabetic foot care 
and wound healing and will only be successful when other impediments to healing 
are addressed.Biologics: Targets & Therapy 2008:2(1) 2
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This review will examine the scientiﬁ  c underpinnings 
supporting the use of becaplermin (Regranex®; Ortho-
McNeil Pharmaceutical, Raritan, NJ), or recombinant human 
platelet-derived growth factor (rhPDGF-BB), in diabetic 
forefoot wounds. As of this writing, becaplermin is the only 
growth factor approved by the United States Food and Drug 
Administration (FDA) for use in diabetic forefoot ulcers. We 
will review the basic tenets of proper medical and surgical 
care of diabetic foot wounds, as the success of this growth 
factor in accelerating healing is so intimately dependent on 
proper ulcer care. We will also outline our indications for the 
use of becaplermin, with a focus on the cost-effectiveness 
of this form of therapy.
Pathogenesis of diabetic foot ulcers
A variety of factors contribute to the pathogenesis of foot 
ulcers in diabetic patients, including peripheral neuropathy, 
ischemia, trauma, and infection (Table 1). Diabetic foot 
ulcers share several causative factors with other types of 
chronic wounds, including local tissue hypoxia, repetitive 
ischemia-reperfusion (IR) injury, bacterial colonization, 
and altered cellular and systemic stress responses. However, 
the diabetic foot ulcer is unique in several regards (Medina 
et al 2005).
The most signiﬁ  cant factor unique to the development 
of ulceration is peripheral neuropathy (symmetrical distal 
polyneuropathy), which affects all nerve ﬁ  ber types in the 
foot. Neuropathy of the motor ﬁ  bers leads to weakness, 
muscle atrophy, and paresis. The intrinsic muscles in the 
foot are disproportionately affected, while the extrinsic 
muscles (represented by the long ﬂ  exor and extensor tendons 
originating in the calf) retain most of their strength and 
mechanical power. This upsets the delicate balance inherent 
to the function of the intrinsic foot muscles so important for 
normal gait pressure patterns and results in the typical posture 
of a diabetic foot. In severe cases this leads to a “Charcot 
foot” with a claw-type posturing and most importantly to 
the transfer of most of the pressure during the gait cycle 
to the area underneath the metatarsal heads. The pressure 
placed under the metatarsal heads is usually alleviated by 
a fat pad; interestingly, this fat pad is often either lost or 
displaced in the diabetic foot. Concomitantly, a sensory 
neuropathy abolishes the protective function of the pain 
ﬁ  bers. The patient is unable to sense minor trauma to the 
foot (for example, a small pebble under a sock or friction 
from a poorly-ﬁ  tted shoe). As trauma is additive throughout 
the several thousand steps taken daily, even a small insult 
can result in overt cumulative injury. Finally, autonomic 
nerve ﬁ  ber dysfunction causes altered vasomotor control 
of the microcirculation and adversely affects inﬂ  ammatory 
cascades, as well as causing anhidrosis of the plantar foot. The 
dry skin can lead to ﬁ  ssuring (which serves as an entry portal 
for bacteria) and aggravates plantar hyperkeratosis at areas 
of friction. Together, these deﬁ  ciencies promote abnormal 
biomechanics during weight-bearing and ambulation that lead 
to unrecognized repetitive trauma. The skin at sites such as 
the plantar surface beneath the metatarsal heads or pressure 
points from poorly ﬁ  tting shoes becomes prone to an injury 
that progresses into a chronic wound (Boulton et al 2004; 
Cavanagh et al 2005; Wieman 2005).
Local tissue hypoxia is also a major component of many 
diabetic foot ulcers. Regional tissue ischemia resulting from 
peripheral vascular disease complicates a large number of 
the wounds. Diabetic patients develop a stereotypical pattern 
of lower extremity atherosclerotic lesions in a more periph-
eral distribution when compared to non-diabetic patients. 
However, even limbs free from overt arterial insufﬁ  ciency 
may suffer from a number of abnormalities in the micro-
circulation that contribute to local tissue hypoxia. Diabetic 
microangiopathy is characterized by distinct functional 
abnormalities and aberrant angiogenesis, resulting in 
impaired vasodilation and physiological responses to hypoxia 
(LoGerfo et al 1984; Rayman et al 1986; Rayman et al 1995; 
Jaap et al 1996; Martin et al 2003).
The repetitive nature of the trauma occurring at the 
vulnerable pressure points on the diabetic foot likely causes 
cyclical bouts of cutaneous ischemia-reperfusion (IR) injury. 
The effects of IR injury have been studied extensively in other 
organs such as the heart and brain. However, the hypothesis 
that cutaneous IR injury plays a role in chronic wounds has 
only recently been explored. On a molecular level, the injury 
process is initiated when adenosine triphosphate (ATP) 
production is reduced during ischemia, leading to cellular 
events that result in leukocyte activation, oxidative stress, 
and microvascular dysfunction upon reperfusion. Similar 
Table 1  A variety of factors contribute to the pathogenesis of 
a diabetic foot ulcer
Peripheral neuropathy
Ischemia
Trauma
Infection
Local tissue hypoxia
Ischemia-reperfusion injury
Bacterial colonization
Altered cellular and systemic stress responsesBiologics: Targets & Therapy 2008:2(1) 3
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to other chronic wounds, both reperfusion and the additive 
effects of repetitive IR cycles can escalate the amount of 
injury in diabetic ulcers. With already altered mediators of 
IR injury, diabetic patients appear to experience a further 
delay in wound healing (Mustoe et al 2006).
Although not strictly a precipitating factor in diabetic 
foot ulcer development, an infection can quickly become 
established in the foot with the initial injury serving as an 
ingress for bacteria past the barrier defenses of intact skin. 
An impaired leukocyte response allows rapid spread of the 
infectious process, leading to added morbidity with further 
impaired healing, propagation of tissue damage, increased 
hospitalization, and ultimately amputation in a signiﬁ  cant 
proportion of cases (Boulton et al 2004; Falanga 2005).
Molecular and metabolic 
derangements of healing in diabetic 
patients
The molecular pathways that culminate in wound heal-
ing deficiencies in diabetic individuals have been the 
focus of numerous studies. From a biochemical approach, 
metabolic mechanisms have been demonstrated to result 
in increased oxidative stress in cell types susceptible to 
hyperglycemia. Brownlee (2005) has recently laid out a 
unifying hypothesis that places the overproduction of reac-
tive oxygen species (ROS) at the center of the four main 
biochemical derangements present in hyperglycemia: (1) 
overstimulation of the protein kinase C (PKC) signaling 
pathway, (2) overproduction and accumulation of advanced 
glycation end products (AGES), (3) increased accumulation 
of the sorbitol pathway, and (4) increased ﬂ  ux through the 
hexosamine pathway (Figure 1).
These molecular derangements have demonstrable clinical 
implications. For example, sorbitol accumulation in nerves 
and their vasa nervosum is thought to contribute to the poly-
neuropathy present in diabetic patients (Engerman et al 1994; 
Gabbay et al 1966). The increase in PKC can result in altera-
tions in microvascular blood ﬂ  ow, in part through deranged 
nitric oxide expression, hexosamine pathway abnormalities, 
vessel matrix thickening from transforming growth factor-
β (TGF-β) signalling, and increased inﬂ  ammation through 
nuclear factor-kappa B (NF-κB) cascades (Ishii et al 1996; 
Koya et al 1998). Finally, AGES accumulate in tissues with 
slow turnover, such as tendons and skin, causing increased 
stiffness and thickness. By actions through their receptor 
(RAGE), they can also induce a pro-inﬂ  ammatory phenotype 
(Hammes et al 1991; Schmidt et al 1995; Brownlee 2005).
Cells such as the ﬁ  broblasts and macrophages display 
both dysfunctional expression of and responses to many 
growth factors and cytokines. Affected signalling molecules 
include platelet-derived growth factor (PDGF), TGF-β, 
vascular endothelial growth factor (VEGF), tumor necrosis 
factor-α (TNF-α), interleukin-1 (IL-1), matrix metallopro-
teinases (MMP’s), among others (Bennett et al 1993; Cross 
et al 2003). It is therefore not surprising that most growth 
factor monotherapies have proven to be ineffective in healing 
diabetic ulcers (Robson et al 1998). PDGF may be an excep-
tion, since it has pleiotrophic effects on a variety of cell types 
(Pierce et al 1991). The induction of a senescent-like phe-
notype has also been proposed as a theory for the impaired 
activities of these cells, likely resulting from the chronic 
Glycolysis
↑ glucose sorbitol pathway polyneuropathy
↑ glucose-6-P
↑ fructose-6-P hexosamine pathway microvascular flow abnormalities
↑ glyceraldehyde-3-P protein kinase C pathway microvascular flow abnormalities
aberrant angiogenesis
AGE pathway - pro inflammatory genes
↑ 1,3-diphosphoglycerate
↑ ROS   → ↓ GAPDH
Figure 1 Hyperglycemia induces biochemical derangements in susceptible cells that increases free radical production, activates 4 pathways of cellular damage, and 
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oxidative stress induced by hyperglycemia or by age. Growth 
factor therapy may “rescue” these senescent cells by activat-
ing them to enter the cell cycle or by stimulating receptive 
cells in a milieu that is relatively deﬁ  cient in growth factors 
(Blazer et al 2002; Mustoe et al 2006).
Current management strategies 
for diabetic foot ulcers
The overall management of chronic diabetic foot ulcers has 
improved as a result of national and international health care 
efforts to assemble scientiﬁ  c data, foster expert discussion, 
and develop consensus opinions and recommendations 
(Apelqvist et al 2000; Frykberg et al 2006; Steed et al 2006). 
The care of diabetic foot ulcers is ideally rendered through 
a multi-disciplinary approach. The value of prevention 
cannot be over-emphasized. Responsible glycemic control, 
appropriate footwear, good foot hygiene and care, appropri-
ate management of comorbidities, and disease education are 
basic elements should be incorporated into the life-style of all 
diabetic patients. Some authors suggest that these practices 
can decrease the occurrence of foot ulcers by up to 50% 
(Boulton et al 2004; Rathur et al 2007).
The vascular, neurological, and infectious states of the 
limb form the tripod supporting all subsequent management 
of the diabetic foot. Evaluation of the vasculature begins 
with the assessment of pulses and noninvasive evaluation 
of the peripheral circulation. Appropriate consultation of a 
vascular surgeon can then be undertaken for possible revas-
cularization or alternative interventions to optimize blood 
supply and perfusion. Neuropathy can be evaluated with 
methods such as sensory testing with a nylon monoﬁ  lament 
(Semmes-Weinstein 5.07/10 g monoﬁ  lament) or biothesiom-
eter, along with the physical exam (Steed et al 2006).
Infection must be treated aggressively. Early sharp 
debridement should be performed to remove all necrotic 
tissue, followed by a deep tissue culture. In all cases of local 
infection, the possibility of osteomyelitis should always 
be entertained. The wound should be probed to determine 
whether it tracks into bone or tendon. If so, broad spectrum 
antibiotics and further surgical debridement are necessary. 
Frequent and adequate sharp debridement on a regular basis 
has been shown to decrease wound healing times. Speciﬁ  -
cally, debridement accomplishes three functions: (1) it clears 
devitalized tissue and bioﬁ  lm; (2) it removes callus, which 
serves only to increase pressure; (3) it converts a chronic, 
stagnant wound into an “acute” wound, which is ready to 
progress through the normal phases of wound healing. The 
most important principle of local wound care after achieving 
a clean wound bed consists of maintaining a clean, moist 
healing environment. Dressing selection need not be fancy 
but should match the wound characteristics and be tailored to 
the wound exudate level to achieve the ideal moist conditions 
on the wound surface (Wieman 2005; Brem et al 2006; 
Rathur et al 2007).
The principle of off-loading is crucial to eliminating the 
trauma that not only precipitated the diabetic foot ulcer but 
may subsequently prevent its healing. This aspect of the 
wound care is perhaps one of the most difﬁ  cult for patients to 
adhere. The consequences of a lapse in adequate off-loading 
that reinitiates IR injury are not trivial and can undo weeks 
of healing progress. Indeed, this is the most common cause 
of recidivism in a healed ulcer. Modalities of off-loading, 
including orthotics, casts, boots, and foam dressings, must 
be individualized to the patient. The total-contact cast (TCC) 
represents the current gold-standard for off-loading. Remark-
ably, most ulcers will eventually heal solely with the use of 
a TCC and proper conservative wound care. Unfortunately, 
all forms of off-loading require large expenditures in terms 
of supplies and personnel, as well as a ﬁ  rm commitment to 
their proper use by the patient (Mustoe et al 2006; Wu et al 
2006; Rathur et al 2007).
Adjunctive and alternative therapies are generally con-
sidered if the implementation of standard strategies has not 
resulted in acceptable healing of the foot ulcer. Weekly or 
biweekly measurements are important in this regard, as they 
will identify as early as possible those wounds that have 
stalled or have fallen off the trajectory of expected healing 
(Steed et al 2006). Becaplermin, tissue-engineered skin sub-
stitutes, low-frequency ultrasound, negative-pressure therapy 
(V.A.C.; KCI, Inc., San Antonio, Texas), and hyperbaric 
oxygen therapy (HBOT) have all had promising results in 
clinical trials and are being utilized more often for difﬁ  cult 
non-healing foot ulcers. Other interventions such as electrical 
stimulation, light-emitting diodes, and hydrotherapy do not 
have clear supporting data at this time (Boulton et al 2004; 
Steed 2006).
Surgical procedures have been advocated for selected 
cases. An amputation may sometimes be more desirable 
instead of a prolonged effort at limb salvage, particularly in 
patients with unreconstructable vascular supply and active 
infection or gangrene. However, efforts to preserve a limb 
are generally worthwhile, due to the overall deleterious 
effects of leg amputations in these patients. Metatarsal head 
resections can be designed to be beneﬁ  cial in relieving 
pressure points on the plantar foot surface. More proximal 
hindfoot amputations, despite their unappealing cosmetic Biologics: Targets & Therapy 2008:2(1) 5
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appearance and the relative inexperience of many pedorthists 
in designing prostheses for such stumps, are nevertheless 
useful in diabetic patients to maintain ambulatory ability with 
minimal increases in energy expenditure (Waters et al 1976; 
Pinzur et al 1992; Stone et al 2005). Reconstructive plastic 
surgical procedures are extremely useful for covering areas 
of exposed bone or tendon, for larger defects, and for defects 
of the midfoot and hindfoot (Attinger et al 2002). Some 
have advocated Achilles tendon lengthening to reduce the 
pressure on forefoot plantar ulcers (Mueller et al 2003; Steed 
et al 2006). Other procedures such as a tarsal tunnel release 
have shown promise in cases of distal polyneuropathy, with 
evidence of superimposed nerve compression, but these 
interventions require further evaluation for efﬁ  cacy at this 
time (Valdivia et al 2005; Chaudhry et al 2006).
Growth factor therapy for chronic 
wounds
Despite adequate care of diabetic foot ulcers, many 
neuropathic ulcers on non-ischemic limbs heal slowly or 
fail to heal, increasing the risk of infections and subsequent 
amputations. Surgical options for closure may be limited 
due to comorbidities in these often ill patients. The need 
for new modalities has spurred the application of molecular 
therapeutics, in particular growth factors, to the care of 
chronic wounds. The use of growth factors as vulnerary 
agents in preclinical models arose soon after their discovery. 
In the 1980s, PDGF became the ﬁ  rst growth factor that was 
isolated and puriﬁ  ed to homogeneity. Concurrently, other 
studies had demonstrated the integral roles of factors such 
as PDGF, TGF-β, and ﬁ  broblast growth factor (FGF) in 
wound healing. Clinical studies, meanwhile, had shown that 
levels of several important growth factors were signiﬁ  cantly 
decreased in chronic wounds when compared to acute 
surgical wounds. With these novel ﬁ  ndings regarding the cell 
biology of chronic wounds, the rationale that the replacement 
or addition of growth factors to the wound milieu would lead 
to a positive effect on wound healing certainly appeared 
promising (Mustoe et al 1991; Pierce et al 1988, 1991).
However, with the exception of PDGF, growth factor 
monotherapies for chronic wounds have not developed into 
successful therapeutics. One fundamental problem involves 
the local protease-rich environment of a chronic wound, which 
has been shown to actively degrade and inactivate most growth 
factors. This ﬁ  nding may explain in part the altered levels of 
growth factors in chronic wounds, but it also suggests that 
topical therapeutic applications probably allow only a brief 
suboptimal exposure of the wound to the growth factor unless 
the protease-rich, pro-inﬂ  ammatory wound environment is 
ﬁ  rst addressed (Robson et al 1998; Cross et al 2003).
PDGF was ﬁ  rst identiﬁ  ed as a mitogen for ﬁ  broblasts and 
smooth muscle cells (SMC’s). The growth factor was subse-
quently found to also induce chemotaxis for these cells and 
other cells that enter the healing wound, such as neutrophils and 
monocytes. It was initially isolated from platelets but was later 
shown to be produced by most of the activated cells present in 
the wound milieu. One principal effect of PDGF on wound heal-
ing is the stimulation of extracellular matrix (ECM) synthesis 
and collagen production. Once activated, ﬁ  broblasts produce 
provisional matrix components such hyaluronic acid and ﬁ  bro-
nectin. Eventually, the synthesis of type I collagen leads to the 
development of wound strength. PDGF is also known to acti-
vate several intracellular signaling cascades through different 
receptors, leading to its pleiotropic effects in a wound (Pierce 
et al 1988; Pierce et al 1991; Ross et al 1974).
These effects of PDGF do not remain constant but differ 
over the course of the wound healing process (Figure 2). In 
the early days after injury, the growth factor is released from 
platelets and endothelial cells. It serves as a chemotactic signal 
for neutrophils, macrophages, and ﬁ  broblasts to the damaged 
tissue. Continued stimulation of these cells after their arrival 
to the wound leads to endogenous production of PDGF, pro-
visional ECM synthesis, ﬁ  broblast proliferation, and collagen 
production. After 2–3 weeks, PDGF signaling contributes to 
wound remodeling by orchestrating active collagen turnover 
and cross-linking. The temporal changes in the effects of PDGF 
appear to be determined in part by its relative concentration 
Figure 2 The cellular sources and effects of PDGF vary throughout the wound 
healing process.
Abbreviations: ECM, extracellular matrix; PDGF, platelet-derived growth factor.
Time Stages of
wound healing
Major sources
of PDGF
Effects
of PDGF
Injury Hemostasis Platelets
endothelial cells
Chemotaxis
of neutrophils,
macrophages,
ﬁ  broblasts
Inﬂ  ammatory Activation
of macrophages
& ﬁ  broblasts
Endogenous GF 
production
ECM synthesis
Fibroblast proliferation
Collagen synthesis
5–7 days Proliferative Macrophages
ﬁ  broblasts
2–3 weeks Remodeling Collagenase expression
Active collagen turn-
over & cross-linking
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to other important growth factors such as TGF-β, insulin-like 
growth factor-1 (IGF-1), IL-1, epidermal growth factor (EGF), 
and TNF-α (Bennett et al 2003; Cross et al 2003).
As has been previously discussed, the care of a diabetic 
foot ulcer is not a minor endeavor. Many practitioners do not 
address all the disparate contributors (vascular, neuropathic, 
infectious, and biomechanical) to a foot ulcer. Poor compliance 
with wound care and off-loading remain a frustrating cause of 
therapeutic failures as well as recidivism. Bioﬁ  lm recalcitrance 
can also become a frustrating aspect of ulcer care. All of these 
“real-world” practice considerations result in healing rates that 
do not match those seen in clinical trials; this is often not taken 
into account when evaluating efﬁ  cacies of therapeutics such as 
becaplermin. It is also important to emphasize that the etiopa-
thology of a diabetic foot ulcer does not result from a growth 
factor deﬁ  ciency per se, but rather from a traumatic insult in 
the setting of peripheral neuropathy, with variable contributions 
from musculotendinous derangements, local and regional isch-
emia, and infection. Adding a growth factor to a wound without 
addressing these factors will be a futile exercise.
Becaplermin as a therapeutic agent 
and evidence for clinical efﬁ  cacy 
in diabetic forefoot ulcers
Several important pre-clinical animal studies demonstrated the 
potential of PDGF as a therapeutic agent for wound healing. 
These studies stemmed from the observations that most of 
the cell types entering the wound are capable of synthesizing 
PDGF and are also activated by PDGF and the hypothesis 
that exogenous application of PDGF could amplify its pro-
liferative effect through an autocrine feedback loop (Pierce 
et al 1991). One study utilizing a rat incisional wound model 
showed increased inﬂ  ammatory response, wound cellularity, 
granulation tissue formation, neovascularization, and epithe-
lialization in PDGF-treated wounds the over control wounds. 
Along with those parameters, an accelerated wound healing 
rate and increased wound breaking strength were also shown 
(Pierce et al 1988). Another study performed in a rabbit ear 
excisional wound model revealed signiﬁ  cantly increased 
re-epithelialization and granulation tissue formation in the 
PDGF-treated wounds (Mustoe et al 1991). Furthermore, 
studies of impaired wound healing in a diabetic mouse strain 
demonstrated a reversal of the deﬁ  cient healing phenotype 
with PDGF treatment (Greenhalgh et al 1990).
These successful animal studies led to human clinical 
trials investigating the potential of exogenous PDGF therapy 
for healing chronic wounds. Initial trials were carried out 
in the setting of pressure sores and suggested that PDGF 
treatment had therapeutic value in the acceleration of chronic 
wound healing. However, continued studies in this patient 
population did not appear to bear out these ﬁ  ndings (Mustoe 
et al 1994). Other trials, which focused on diabetic foot 
ulcers, produced statistically signiﬁ  cant ﬁ  ndings that even-
tually led to FDA approval for use in this subset of chronic 
wounds (Steed 1995; d’Hemecourt et al 1998; Wieman et al 
1998; Smiell et al 1999).
When it was approved by the FDA in 1997 for the treat-
ment of chronic lower extremity diabetic neuropathic ulcers, 
rhPDGF-BB became the ﬁ  rst and remains the only pharmaco-
logical agent approved for treatment of a chronic wound condi-
tion. This recombinant growth factor is delivered in a topical 
aqueous-based sodium carboxymethylcellulose (NaCMC) gel 
and is marketed as Regranex®. The therapy is indicated for 
uninfected diabetic foot ulcers that extend into the subcutane-
ous tissue and have an adequate vascular supply.
The efﬁ  cacy of becaplermin gel treatment was evaluated 
in 4 published multicenter prospective randomized control 
trials (RCTs), which led to its FDA approval. Initially headed 
by Steed and the Diabetic Ulcer Study Group, these trials 
involved a total of 922 patients. The ﬁ  rst two studies were 
double-blinded, while the third and fourth studies were only 
evaluator-blinded because they involved an arm with only 
standard ulcer care. Ulcer criteria for entrance into each 
of these trials included the following: wound presence for 
greater than 8 weeks, absence of infection, presence of an 
adequate vascular supply, and presence of good wound care. 
Ulcer sizes were restricted to those between 1 cm2 and 100 
cm2, but only the ﬁ  rst trial included those larger than 40 cm2, 
and over 95% of the wounds had areas of less than 10 cm2. 
All of the wounds were sharply debrided to obtain a clean 
wound bed before randomization; however, one limitation 
of these trials was the variable debridement regimens that 
followed. The treatment protocol for the application of 
becaplermin gel and dressing changes remained consistent 
throughout the studies. On the other hand, patient adherence 
to important aspects of diabetic ulcer care such as off-loading 
appeared to be variable. The trials all continued for 20 weeks 
to evaluate complete wound closure as the primary endpoint, 
but the only reported follow-up after the conclusion of each 
study was a 3-month period. The results were analyzed using 
multiple statistical methods that were appropriate for the 
data presented. Becaplermin appeared to have an acceptable 
safety proﬁ  le, was well-tolerated by the patients, and could 
easily be used by the patients or their caregivers (Steed 1995; 
d’Hemecourt et al 1998; Wieman et al 1998; Smiell et al 
1999; Steed 2006).Biologics: Targets & Therapy 2008:2(1) 7
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The ﬁ  rst study was a multicenter double-blinded RCT that 
compared becaplermin gel (30 μg/g) against a placebo gel 
(NaCMC) for clinical efﬁ  cacy and safety (Steed 1995). This 
Phase II trial was the ﬁ  rst to investigate PDGF in human dia-
betic ulcers and recruited 118 patients. The authors reported a 
statistically signiﬁ  cant greater incidence of complete healing 
in the treated wounds (48% vs 25%, p = 0.02).
A subsequent Phase III trial assigned 382 patients to 
becaplermin gel (30 μg/g and 100 μg/g) and placebo gel 
treatment groups (Wieman et al 1998). The becaplermin-
treated wounds had higher incidences of complete healing 
over the study period, but only the 100 μg/g becaplermin 
dose yielded statistically signiﬁ  cant results when compared 
to placebo gel (50% vs 35%, p = 0.01).
The third smaller study randomized a total of 138 patients 
to placebo gel treatment and good ulcer care comparison 
groups, in addition to a smaller group of 34 patients who 
opted to receive active becaplermin gel treatment (100 μg/g) 
instead (d’Hemecourt et al 1998). The becaplermin group was 
apparently not powered for statistical comparison of wound 
healing because the primary goal of this trial was to compare 
the safety of the placebo gel group against good ulcer care. The 
complete wound healing incidences were reported to be 44% 
for becaplermin gel treatment, 36% for placebo gel treatment, 
and 22% for good ulcer care only. However, these outcomes 
were not statistically signiﬁ  cant at the p  0.05 level.
A fourth trial of 250 patients was designed to assess resource 
utilization by comparing becaplermin gel treatment (100 μg/g) 
against good ulcer care alone. The study did not demonstrate a 
statistically signiﬁ  cant difference in complete wound healing 
incidences between the two groups (36% vs 32%), although 
the authors did note that a trend in favor of becaplermin gel 
treatment appeared to be present (Smiell et al 1999).
An additional post-marketing Phase IV trial was per-
formed with the goal to demonstrate becaplermin gel treat-
ment efﬁ  cacy against that of good ulcer care (Robson et al 
2005). The main difference in the treatment design of this 
trial as opposed to the four previous pre-marketing RCTs 
was that this study utilized a once-daily application instead 
of a twice-daily application of becaplermin gel. The study 
was also limited by the fact that it did not achieve full accrual 
of patients. Therefore, it was not appropriately powered for 
statistical comparison of complete wound healing incidences. 
For the 146 out of the 340 planned patients, the reported 
complete healing incidences were 42% for becaplermin gel 
treatment and 35% for good ulcer care (p = 0.316).
Recent meta-analyses have been performed to reconcile 
the data from these RCTs (Smiell et al 1999). A logistic 
regression model showed that for a median wound size of 
1.5 cm2, the probability of complete healing was increased 
39% with the administration of becaplermin gel (100 μg/g) 
over placebo gel alone (50% vs 36%, p = 0.007). Similar 
results were found when comparing becaplermin gel treat-
ment to only good ulcer care. Analysis of the data using a 
Cox proportional hazards model suggested that becaplermin 
gel (100 μg/g) treatment also signiﬁ  cantly decreased the 
time to achieve complete wound healing in comparison to 
placebo gel treatment (p = 0.01). Using the Kaplan-Meier 
method, this difference in healing time was estimated to be 
30% less for becaplermin gel at the 35th percentile level 
(14.1 weeks vs 20.1 weeks). Robson et al also performed 
a meta-analysis after the Phase IV trial to integrate those 
results with the previous RCTs. While the Phase IV study 
itself did not reveal statistically signiﬁ  cant results, the overall 
meta-analysis results did not deviate remarkably from that 
of the ﬁ  rst four RCTs.
Some important issues in studying human wound healing 
therapeutics have been highlighted by these trials. In this 
regard they can be considered bellwether studies in the ﬁ  eld 
of wound care. The baseline variability of wound healing 
is particularly notable and is illustrated in these studies as 
the wound closure rates for the placebo gel treatment and 
standard care groups ranged from 23% to 36%. Similarly, 
the becaplermin treatment groups also had wound closure 
rates that varied from 36% to 50%. With such variability, 
trials enrolling as many as 200 patients may still be under-
powered to demonstrate a treatment effect (Mustoe 2006). 
The durability of the treatment effect is another consideration 
of such wound healing studies and has implications for the 
cost-effectiveness of the therapy. In these becaplermin trials, 
the follow-up included a 3-month period after the 20-week 
study period ended. The recurrence rate was found to be 
28%, regardless of the treatment group. Importantly, there 
was not a standardized regimen of ulcer prevention strategies 
implemented during this three month period. While recur-
rence may have likely been primarily dependent on patient 
compliance to continued wound and foot care strategies, it 
remains a concern when extrapolating these trial results to 
routine clinical practice.
While the ability to demonstrate a treatment effect with 
becaplermin represents a giant step forward in the treatment 
of chronic wounds, many concerns about the management of 
diabetic foot ulcers with becaplermin remain to be answered. 
The becaplermin trials only studied diabetic forefoot 
ulcers, which are typically smaller and less prone to ischemia 
than midfoot or hindfoot ulcers. Comparison of becaplermin Biologics: Targets & Therapy 2008:2(1) 8
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gel to other modalities, such as the living bilayered 
construct, Apligraf® (Organogenesis, Inc., Canton, MA), 
has not been performed. These studies also did not compare 
becaplermin therapy to a rigorous off-loading regimen, 
which has actually been shown to heal a large proportion of 
foot ulcers (Wu et al 2006). Other variables such as patient 
co-morbidities, osteomyelitis, bioﬁ  lm, and debridement 
regimens will certainly remain challenges for assessing the 
use of becaplermin. Nevertheless, in the appropriate clinical 
scenarios, the utilization of becaplermin gel as an adjunct to 
diabetic foot ulcer care can lead to improved results.
Economic analyses of becaplermin 
therapy
The burdensome strains of diabetic complications exist on 
personal, social, medical, and economical levels. Depend-
ing on the viewpoints that are considered, the costs and 
consequences can vary dramatically. While personal losses 
such as pain and suffering are difﬁ  cult to quantify, multiple 
analyses have been conducted to study the ﬁ  nancial impact 
of diabetes on the national health care system, the economy, 
and the society. Direct health care costs in the United States 
for diabetes are estimated to be over US$90 billion annually, 
consuming approximately 10% of national health care 
expenditures. One-third of this spending is directed to the care 
of diabetic complications. Another US$42 billion of indirect 
costs result from lost productivity, disability, and mortality 
(Centers for Disease Control and Prevention 2005).
A logical question has focused on the cost-effectiveness 
of implementing becaplermin therapy. Although raising the 
initial costs, the beneﬁ  ts in the long run potentially result in 
overall cost savings. Sequelae such as infection and gangrene 
result in additional hospitalizations and possible amputa-
tions, adding signiﬁ  cant morbidity and cost to the care of 
diabetic foot ulcers. By improving the treatment efﬁ  cacy 
of neuropathic ulcers, becaplermin would likely reduce the 
risk for the development of lower extremity infections and 
gangrene. In summary, any modality that improves overall 
wound healing, and prevents additional hospitalization and 
amputation, would likely be cost-effective in monetary terms 
and certainly efﬁ  cacious in reducing patient morbidity.
With the caveat that economic analyses of clinical 
scenarios inherently contain many limitations, those 
examining the treatment of diabetic foot ulcers have suggested 
that becaplermin in conjunction with good wound care may 
be cost-effective (Table 2). In a study published in 2001, 
Kantor and Margolis (2001) estimated the cost-effectiveness 
of becaplermin therapy in comparison to the modalities 
of standard care, specialized care at a wound care center, 
and treatment with platelet releasate. They performed a 
deterministic analysis by utilizing data from published 
sources. Conducted from the viewpoint of the payer, the study 
used Medicare data to proxy for costs, thereby not considering 
indirect costs. Effectiveness data were derived from RCTs 
and meta-analyses focusing on treatments for neuropathic 
ulcers, including those investigating becaplermin. For their 
analyses, effectiveness was deﬁ  ned in terms of percentage of 
the wound healed at 20 weeks and 32 weeks. The study period 
was limited to the length of the clinical trials. Incremental 
cost-effectiveness ratios that were computed suggested that 
becaplermin therapy had the most favorable marginal costs 
associated with each additional percentage increase in healing 
at 20 weeks.
Given the potential impact of becaplermin therapy beyond 
the treatment period, Persson et al (2000) attempted to extrapo-
late their data to 1- and 2-year time points by developing a 
Markov economic model to simulate the management of dia-
betic foot ulcers. This approach is useful for studying clinical 
problems that involves a continuous risk, events that may occur 
multiple times, and outcome utilities that depend on the timing 
of different events. The costs were examined from a payer’s 
viewpoint in the Swedish health care system and were based 
on a cohort study of 314 Swedish patients. The efﬁ  cacy of 
good wound care was based on a 9 month follow-up study on 
194 diabetic patients in the United States with neuropathic foot 
Table 2  Recent cost-effectiveness studies of becaplermin usage 
in diabetic foot ulcers have suggested an overall cost savings for 
their use
Study Type  Conclusions
Kantor and  Deterministic  Compared becaplermin to stan-
Margolis (2001)  analysis  dard care, care at wound center,
    and platelet releasate treatment
    Becaplermin had the most 
    favorable marginal costs associ
    ated with each percentage 
    increase of healing
Persson et al  Markov   Compared becaplermin to stan-
(2000)  model  dard care Becaplermin treatment 
    resulted in a 24% increase of 
    ulcer-free months and a 9% 
    decrease in the amputation rate 
    over a 2-year period, while 
    consuming less overall resources
Sibbald et al  Decision analytic  Compared becaplermin to stan-
(2003)  model  dard care Incorporation of beca
    plermin treatment with standard 
    care resulted in 26 fewer ulcer-
    days over 1 yearBiologics: Targets & Therapy 2008:2(1) 9
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ulcers. Becaplermin treatment efﬁ  cacy was derived from the 
four major RCTs. In contrast to the previous study, effective-
ness was analyzed in terms of the number of ulcer-free months 
per year. Interestingly, their results suggested that becaplermin 
therapy with good wound care was actually a win-win situ-
ation, in which becaplermin treatment both consumed less 
overall resources and generated better outcomes than standard 
wound care alone (Sonnenberg et al 1993; Drummond et al 
1997; O’Brien et al 1997; Sibbald et al 2003).
Other approaches of evaluating cost-effectiveness include 
quality of life (QOL) studies, despite the increased difﬁ  culty in 
quantifying the relevant variables. Recent studies employing 
this method have suggested that the QOL scores between 
patients who have suffered lower extremity amputations due 
to trauma and those who have been reconstructed were actually 
similar. However, the diabetic patient population should be 
distinguished from these patients. The increased cardiovascular 
morbidity from an amputation in a diabetic patient is signiﬁ  cant, 
and the avoidance of this outcome warrants intensive efforts 
at foot salvage (Sibbald et al 2003).
Recommendations for becaplermin 
utilization
The current management paradigm of diabetic neuropathic 
foot ulcers involves maximizing the standard treatment strate-
gies discussed earlier. For the majority of non-ischemic and 
uninfected wounds, this treatment regimen should result in 
complete healing. These principles echo guidelines published 
by organizations such as the American Diabetes Association, 
the College of Foot and Ankle Surgeons, the International 
Working Group on the Diabetic Foot, and the Wound Healing 
Society (Apelqvist et al 2000; Brem et al 2006; Steed et al 
2006; Rathur et al 2007).
Most authorities recommend utilizing becaplermin as 
an adjunct therapy for those foot ulcers that do not respond 
acceptably to optimized standard strategies. For example, 
Steed et al (2006) considers becaplermin therapy for any 
patient with a diabetic foot ulcer in which standard care does 
not result in wound reduction by at least 40% in 4 weeks, and 
we would endorse his recommendations (Figure 3). However, 
the utility of employing becaplermin therapy earlier in those 
patients with wounds at high risk for failure, such as large foot 
ulcers, or employing becaplermin therapy in patients with 
uncomplicated wounds remains unclear (Wieman 2005). In 
the case of aged patients (70 years), we will more readily 
add becaplermin to ulcer therapy, as there are likely more 
senescent cells and a relative growth factor deﬁ  ciency that 
may derive more beneﬁ  t from growth factor supplementation 
(Mustoe et al 2006). Clinical data to support this use are 
currently being gathered.
Conclusion
Although becaplermin is currently only approved for use 
in neuropathic diabetic foot ulcers, the potential beneﬁ  t 
of PDGF therapy may still exist in other difﬁ  cult chronic 
wounds. For pressure sores, the early clinical trials unfor-
tunately did not appear to bear promising results. However, 
wounds that develop in patients who are undergoing anti-
angiogenic treatment, are receiving radiation therapy, or have 
both diabetes and renal failure remain problematic and may 
beneﬁ  t from PDGF therapy.
New forms of growth factor therapy may yet be able to 
modulate the chronic wound healing process to a greater 
degree than becaplermin therapy today. Ongoing inves-
tigations are studying the combination of growth factors, 
the improvement of growth factor vehicles, the utilization 
of tissue engineering constructs with growth factors, the 
interaction of stem cells in conjunction with growth factors, 
and gene therapy modalities. Already, some fruitful efforts 
have yielded a new generation in PDGF therapy, evidenced by 
FDA approval of GEM 21S (Growth-factor Enhanced Matrix, 
rhPDGF-BB, OsteoHealth Company, Shirley, NY) last year 
for the treatment of periodontal bone defects and associated 
gingival recession. This new therapeutic combines rhPDGF-
BB and a synthetic bone matrix to stimulate new bone growth 
while providing a scaffold for that growth to occur.
Nevertheless, it has become clear that new treatment strat-
egies for chronic wounds will need to address multiple factors 
simultaneously, instead of just one aspect of wound healing. 
Future successful therapeutics for diabetic neuropathic ulcers 
will likely parallel the development of effective therapies for 
chronic wounds as a whole. A new generation of growth factor 
therapy may very well be on the horizon for these wounds, 
but such therapeutics will likely need to be integrated into a 
multifaceted regimen to be most effective.
The management of diabetic neuropathic foot ulcers 
continues to be a frustrating problem for all clinicians. Not only 
is the effectiveness of therapy oftentimes inadequate, but the 
costs of treatment continue to soar. For the wounds that fail to 
heal acceptably despite optimized standard care, becaplermin 
gel can potentially bridge the gap to complete healing. As the 
ﬁ  rst, and to date only, growth factor approved for the treatment 
of diabetic foot ulcers, becaplermin has broken new ground 
and has set the standard against which all future modalities 
will be compared. Not trivially, much has been learned from 
the pivotal becaplermin trials about the execution of successful Biologics: Targets & Therapy 2008:2(1) 10
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clinical investigations. These insights can be applied directly 
to the investigation of future modalities in the difﬁ  cult arena 
of wound care. It still remains unclear at this time if the 
effectiveness of becaplermin is signiﬁ  cant enough to warrant 
more liberal use. In the future, it appears hopeful that a new 
generation of growth factor therapy will follow becaplermin 
for the treatment these chronic wounds.
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